Value Adjusted for Debt and Cash: Natera Medical (NTRA)

The market price action for Natera, Inc. (NTRA), which currently stands at 60324.66, confirms the company's dominance in the prenatal diagnostics and oncology monitoring segments. The business leverages extensive clinical data that creates significant barriers to entry for competitors. Meanwhile, operations are complicated by geopolitical supply chain disruptions and patent disputes, while adherence to ESG standards requires the company to strictly control the disposal of biomaterials.

Natera, Inc. (NTRA) transition to positive operating cash flow driven by oncology tests is reflected in the EV chart, confirming an increase in the business's real value. This indicator aggregates market capitalization and net debt, allowing investors to assess the total acquisition cost of the asset, accounting for all liabilities and available cash, to determine the company's fundamental overvaluation.